NCT05539014 (COTB-AVC) is a clinical trial of Data collection in Tuberculosis, Pulmonary, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT05539014?

NCT05539014 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT05539014?

Interventions in NCT05539014: Data collection.

What condition does NCT05539014 study?

NCT05539014 studies Tuberculosis, Pulmonary.

Is NCT05539014 still recruiting?

NCT05539014 is currently recruiting now. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT05539014: COTB-AVC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tuberculosis Cohort Avicenne Hospital

Recruiting now Last updated 18 November 2023

What this trial tests

trial testing Data collection in Tuberculosis, Pulmonary in 250 participants. Currently enrolling.

Timeline

18 January 2023

Primary endpoint
15 October 2027

15 December 2027

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	250
Start date	18 January 2023
Primary completion	15 October 2027
Estimated completion	15 December 2027
Sites	2 locations across France

Drugs / interventions tested

Data collection — full drug profile →

Conditions studied

Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 80, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tuberculosis represents the second highest death rate from an infectious disease in the world, just after COVID-19. The most affected department of France is Seine-Saint-Denis. Since 2005, this department with difficult socio-economic conditions has the highest incidence rate in metropolitan France, higher than that of Paris. In 2012, the reporting rate was 10 times higher among people born abroad compared to those born in France, with the highest rates found among people born in sub-Saharan Africa and Asia. It is proposed to constitute for the first time in France a cohort of patients with tuberculosis disease to better understand the characteristics of patients with unfavorable treatment outcomes and ultimately, to propose solutions to obtain better control of tuberculosis. This study would recruit all patients with tuberculosis disease for at least 4 years associated with 1 year of follow-up for a total duration of the study of at least 5 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

NCT07010562 — A Multi-site, Pre-clinical, Prospective Data Collection Study in Patients Undergoing a Right Heart Catheterization · not yet recruiting
NCT07418359 — Comparison of Patient's Physical Activity Levels According to the Physical Activity Level of Their General Practitioner · recruiting
NCT07197398 — Preoperative Data and the Spinal Spread of Local Anesthetic in Cesarean Section · recruiting
NCT06998797 — Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study · not yet recruiting
NCT07529730 — Outcomes of Surgical Treatment in Patients With Infective Endocarditis · completed

Other recruiting trials for Tuberculosis, Pulmonary

Currently open trials in the same condition.

NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05539014 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05539014.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing